Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  The Lancet

• Publication date

  2017-03-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(17)30397-5PMID 28290994
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [2018 ESC/EACTS Guidelines on myocardial revascularization. The Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS)].

  2019cited by this paper
• Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.

  2016cited by this paper
• Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS.

  2016cited by this paper
• 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

  2016cited by this paper
• The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study.

  2016cited by this paper
• Relation Between Hospital Length of Stay and Quality of Care in Patients With Acute Coronary Syndromes (from the American Heart Association's Get With the Guidelines--Coronary Artery Disease Data Set).

  2016cited by this paper
• Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction

  2016cited by this paper
• Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention.

  2015cited by this paper
• Comparing two correlated C indices with right‐censored survival outcome: a one‐shot nonparametric approach

  2015cited by this paper
• Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI survey.

  2015cited by this paper
• Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials

  2015cited by this paper
• Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates.

  2015cited by this paper
• Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration

  2015cited by this paper
• ESC / EACTS Guidelines on myocardial revascularization

  2014cited by this paper
• Assessing discriminative ability of risk models in clustered data

  2014cited by this paper
• 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous

  2014cited by this paper
• Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial.

  2014cited by this paper
• Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial.

  2014cited by this paper
• Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.

  2014cited by this paper
• 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Ca

  2014cited by this paper
• Nuisance bleeding with prolonged dual antiplatelet therapy after acute myocardial infarction and its impact on health status.

  2013cited by this paper
• Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.

  2013cited by this paper
• A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation).

  2012cited by this paper
• Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting: A Randomized Multicenter Trial

  2012cited by this paper
• Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) Randomized, Multicenter Study

  2012cited by this paper
• Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial.

  2012cited by this paper
• The Evolution of Antiplatelet Therapy in the Treatment of Acute Coronary Syndromes

  2012cited by this paper
• Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

  2009cited by this paper
• Baseline Risk of Major Bleeding in Non–ST-Segment–Elevation Myocardial Infarction: The CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Bleeding Score

  2009cited by this paper
• Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond

  2008cited by this paper
• Clinical Prediction Models

  2008cited by this paper
• Prasugrel versus clopidogrel in patients with acute coronary syndromes.

  2007cited by this paper
• Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials

  2003cited by this paper
• Clinical prediction models: are we building better mousetraps?

  2003cited by this paper
• Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

  2001cited by this paper
• EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION

  2001cited by this paper
• Evaluating the yield of medical tests.

  1982cited by this paper

• Bleeding Risk Prediction in Patients With Atrial Fibrillation Undergoing TAVR: Has the HAR(H)P Finally Hit the Right Note?

  2026cites this paper
• Efficacy and safety of clopidogrel versus aspirin monotherapy for secondary prevention after percutaneous coronary intervention: a GRADE-assessed meta-analysis with trial sequential analysis.

  2026cites this paper
• CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) in 2026.

  2026cites this paper
• Dual Antiplatelet Therapy beyond 1 Year after a Myocardial Infarction Compared with Low-Dose Aspirin Alone: A 3-Year Follow-Up Cohort Study Within the French SNDS Nationwide Claims Database.

  2026cites this paper
• Chinese evidence-based antithrombotic therapy for coronary heart disease

  2026cites this paper
• Acute myocardial infarction following allogeneic hematopoietic stem cell transplantation: A national cohort study.

  2026cites this paper
• Ticagrelor versus clopidogrel in patients with chronic coronary syndrome undergoing percutaneous coronary intervention: A propensity score-matched analysis.

  2026cites this paper
• Prognostic Role of the PRECISE-DAPT Score in Acute Coronary Syndrome and Different Antithrombotic Treatment Strategies.

  2026cites this paper
• Prediction of mortality, bleeding, and ischaemic events in patients with cancer and acute coronary syndrome: a model development and validation study.

  2026cites this paper
• Meta-analysis and external validation of a risk model for gastrointestinal bleeding after percutaneous coronary intervention

  2025influential citation
• Guideline for Chronic Coronary Syndrome - 2025.

  2025cites this paper
• Antiplatelet Therapy in Chronic Coronary Artery Disease Patients With a History of Angioplasty. When is Aspirin Not Enough? A Systematic Review

  2025cites this paper
• ESC Quality Indicators for Post-myocardial infarction Care: Transition and Chronic Coronary Syndrome Phases. Developed in collaboration with the European Association of Preventive Cardiology of the ESC.

  2025cites this paper
• Cost-Utility and Budget Impact Analysis of Pharmacogenetic-Guided Antiplatelet Therapy for Acute Coronary Syndrome in Thailand.

  2025cites this paper
• Prognostic Role of the Precise DAPT Score on Long‐Term Outcomes After Carotid Artery Stenting: A Retrospective Cohort Study

  2025cites this paper
• Validation of the Asian-Dual Antiplatelet Therapy Score.

  2025cites this paper
• Aspirin-Free Prasugrel Monotherapy After Percutaneous Coronary Intervention in Patients With Non-ST Elevation Acute Coronary Syndrome.

  2025cites this paper
• Hemoglobin in cardiogenic shock: the lower, the poorer survival

  2025cites this paper
• Antithrombotic drugs for acute coronary syndromes in women: sex-adjusted treatment and female representation in randomised clinical trials. A clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the ESC Working Group on Thrombosis.

  2025cites this paper
• Antiplatelet Therapy in Heart Disease

  2025cites this paper
• Antithrombotic therapy after stent implantation. One size does not fit all.

  2025cites this paper
• Antithrombotic therapy after coronary artery bypass graft surgery: a Clinical Consensus Statement of the ESC Working Group on Cardiovascular Surgery, the ESC Working Group on Cardiovascular Pharmacotherapy, and the European Association for Cardio-Thoracic Surgery (EACTS).

  2025cites this paper
• Twenty-Year Clinical Experience of the Korea Acute Myocardial Infarction Registry

  2025cites this paper
• Antithrombotic Therapy in the Elderly with Cardiovascular Disease: Walking the Tightrope Between Efficacy and Bleeding Risk—A Narrative Review

  2025cites this paper
• Intravascular imaging vs. angiography alone to guide percutaneous coronary intervention in older adults: a meta-analysis of randomized controlled trials.

  2025cites this paper
• Another Score in the Flood, or a Needed Step Toward East Asian Precision?

  2025cites this paper
• Abbreviated or standard antiplatelet therapy after PCI in HBR patients with chronic kidney disease: a prespecified analysis from the MASTER DAPT trial.

  2025cites this paper
• A risk prediction model for gastrointestinal bleeding in coronary heart disease patients undergoing dual antiplatelet therapy after percutaneous coronary intervention

  2025cites this paper
• Impact of a recent cancer diagnosis on bleeding risk after myocardial infarction

  2025cites this paper
• Management of dual antiplatelet therapy following covered femoropopliteal stenting - Why size matters.

  2025cites this paper
• National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: Comprehensive Australian Clinical Guideline for Diagnosing and Managing Acute Coronary Syndromes 2025.

  2025cites this paper
• Incidence of bleeding and performance of the PRECISE-DAPT score in predicting bleeding in patients on dual antiplatelet therapy after treatment for acute coronary syndrome in Kenya

  2025influential citation
• Machine Learning Models With Prognostic Implications for Predicting Gastrointestinal Bleeding After Coronary Artery Bypass Grafting and Guiding Personalized Medicine: Multicenter Cohort Study

  2025cites this paper
• Association of Prognostic Nutritional Index with Post-Discharge Bleeding After Percutaneous Coronary Intervention in ACS Patients on DAPT

  2025influential citation
• The role of triple antithrombotic therapy in patients with atrial fibrillation and coronary stent insertion

  2025cites this paper
• Gastrointestinal Bleeding in the Older Adult: Pathophysiology, Evaluation, and Management

  2025cites this paper
• Oroxylin A reverses SHP-2 oxidative inactivation in GPVI signaling to suppress platelet activation and thrombus formation

  2025cites this paper
• Short-Term DAPT After Complex PCI With Third-Generation DES: A Post Hoc Analysis of the HOST-IDEA Trial

  2025cites this paper
• Pretreatment With P2Y12 Inhibitors in Contemporary Practice: Where Do We Stand?

  2025cites this paper
• PARIS coronary thrombosis risk score combined with D-dimer to guide new oral anticoagulant antithrombotic therapy in patients with acute coronary syndrome after percutaneous coronary intervention: study protocol for the PRIDE-ACS trial

  2025cites this paper
• Peri‐Procedural Management of Oral Anticoagulant Therapy in Patients Undergoing Percutaneous Coronary Intervention: Insights from the PERSEO Multicenter Registry

  2025cites this paper
• Bleeding risk assessment tools for patients with myocardial infarction: a comparative review and clinical implications

  2025cites this paper
• Long-term outcomes of hydrodynamic ultra-thin strut sirolimus-eluting stent with fluoropolymer containing triflusal: VELAZQUEZ-EPIC26 study.

  2025cites this paper
• Anti-thrombotic and glucose lowering therapy in diabetic patients with coronary artery disease undergoing PCI with stent implantation: A prospective multicenter observational study on prescription patterns and clinical outcomes.

  2025cites this paper
• Improvement in risk prediction for patients with atrial fibrillation and intermediate-risk CHA2DS2-VASc score utilizing highly sensitive cardiac troponin T

  2025cites this paper
• Tailored DAPT: still a theory in search of proof.

  2025cites this paper
• Precision in antiplatelet therapy after ACS - Aiming for individualized care.

  2025cites this paper
• Personalized Treatment of Patients with Coronary Artery Disease: The Value and Limitations of Predictive Models

  2025cites this paper
• Validation of the Mayo Clinic Percutaneous Coronary Intervention Risk Prediction Score in Patients With Acute Coronary Syndrome

  2025cites this paper
• Improving on current guidelines for aspirin-free strategies after percutaneous coronary intervention and future perspectives

  2025cites this paper
• Comparison of in-hospital net clinical outcomes of ticagrelor and clopidogrel in acute coronary syndrome patients stratified by CRUSADE score: findings from the CCC-ACS registry

  2025cites this paper
• Intravascular ultrasound–guided percutaneous coronary intervention in acute coronary syndrome stratified by the TVF-ACS risk score: the IVUS-ACS trial

  2025cites this paper
• Tratamiento de la angina estable

  2025cites this paper
• Combination of Antiplatelet Therapy in Psoriatic Diseases With Cardiovascular Comorbidities: A Thromboinflammatory Perspective in the Era of Biologic Therapies

  2025cites this paper
• Design and rationale of the South-East Netherlands Heart Registry (ZON-HR)

  2025cites this paper
• Prediction of major bleeding events for patients with dual antiplatelet therapy after myocardial infarction—a validation of the PRECISE-DAPT cancer score

  2025cites this paper
• Managing patients with a history of arterial disease and new venous thromboembolism.

  2025cites this paper
• Long-term MACE and bleeding risk prediction using 4-item PRECISE-DAPT vs. DAPT scores in PCI patients with achieved LDL-C < 70 mg/dL.

  2025cites this paper
• Dual Antiplatelet Therapy Duration Following Percutaneous Coronary Intervention: Time for a Change

  2025cites this paper
• Discordance and Performance of the ARC-HBR and PRECISE-DAPT High Bleeding Risk Definitions After Coronary Stenting.

  2025cites this paper
• Sex Differences in the Safety and Efficacy of Different Durations of DAPT After PCI

  2025cites this paper
• Pharmacotherapeutic options for coronary thrombosis treatment: where are we today?

  2025cites this paper
• Contrastive learning with transformer for adverse endpoint prediction in patients on DAPT post-coronary stent implantation

  2025cites this paper
• Parsimonious versus extensive bleeding score: can we simplify risk stratification after percutaneous coronary intervention and reduce bleeding events by de-escalation of the antiplatelet strategy?

  2025cites this paper
• Refining the bleeding risk assessment in patients on DAPT.

  2025cites this paper
• Bleeding Risk After PCI: Do We Need Another Score?

  2025cites this paper
• Characterizing High-Risk Enrollment Criteria and Impact on Clinical Outcomes in a Large Randomized Clinical Trial: Insights From the TWILIGHT Trial.

  2025cites this paper
• Relevance of High Bleeding Risk and Postdischarge Bleeding in Patients Undergoing Percutaneous Coronary Intervention.

  2025cites this paper
• Development and validation of a novel bleeding risk prediction tool for aspirin users with a low body mass index

  2025cites this paper
• Bleeding Risk in Elderly Patients Undergoing Percutaneous Coronary Intervention: A Comprehensive Review

  2025cites this paper
• Genotype-guided de-escalation and abbreviation of dual antiplatelet therapy in patients with myocardial infarction and high bleeding risk: Design and rationale of the investigator-initiated, multicenter, randomized, controlled trial, DAN-DAPT.

  2025cites this paper
• 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

  2025cites this paper
• Efficacy and Safety of Dual Antiplatelet Therapy in High-Risk, Post-Percutaneous Coronary Intervention Patients beyond One Year

  2025cites this paper
• Response.

  2025cites this paper
• Dual antiplatelet pre-treatment with aspirin and ticagrelor in ACS patients undergoing unplanned aortocoronary bypass surgery

  2025cites this paper
• Principles of optimal multidisciplinary management of prostate cancer in clinical practice

  2025cites this paper
• Clinical impact of drug-coated balloon treatment of coronary artery disease in elderly patients.

  2025cites this paper
• Refining DAPT strategies after drug coated balloon angioplasty

  2025cites this paper
• Treatment of non-ST-segment elevation myocardial infarction in the elderly: the SENIOR-RITA trial

  2025cites this paper
• Safety, efficacy, and outcomes of invasive coronary angiography in liver transplant candidates

  2025cites this paper
• The Association Between Peripheral Arterial Disease and Long-Term Bleeding Events in Patients with Acute Myocardial Infarction

  2025cites this paper
• Bleeding Complications of Anticoagulation Therapy Used in the Treatment of Acute Coronary Syndromes—Review of the Literature

  2025cites this paper
• Antithrombotic drugs for acute coronary syndromes in women: sex-adjusted treatment and female representation in randomised clinical trials. A clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the ESC Working Group on Thrombosis.

  2025cites this paper
• Recurrent Events Analysis of MASTER DAPT: Total Ischemic and Bleeding Events After Abbreviated vs Prolonged DAPT in HBR Patient.

  2025cites this paper
• Risk stratification of net adverse clinical events using CHADS-P2A2RC and CHADS2 scores in chronic coronary syndrome patients without atrial fibrillation: Insights from the CLIDAS-PCI.

  2025cites this paper
• Low LDL-Cholesterol and Hemorrhagic Risk: Mechanistic Insights and Clinical Perspectives

  2025cites this paper
• Prolonged dual antiplatelet therapy strategy in acute coronary syndrome patients post-standard therapy and adverse event-free: An analysis based on OPT-CAD risk score stratification.

  2025cites this paper
• External Validation of the PRECISE‐DAPT Cancer Score in Patients With Acute Myocardial Infarction

  2025cites this paper
• Sex related differences in efficacy and safety of antithrombotic therapy in patients with coronary artery disease: systematic review and meta-analysis

  2025cites this paper
• Decoding Bleeding Risks and Survival in Patients Undergoing Percutaneous Coronary Intervention on Antiplatelet Therapy

  2025cites this paper
• Cangrelor in percutaneous coronary interventions: advances in evidence, clinical applications, and future directions

  2025cites this paper
• Preclinical Efficacy of a Hemostatic Agent in Overcoming Dual Antiplatelet Therapy

  2025cites this paper
• Stents coronaires actifs et DAPT : données de la littérature, limites méthodologiques et implications suggérant une prise de décision individuelle optimale

  2025cites this paper
• Antithrombotic therapy after coronary artery bypass graft surgery: a Clinical Consensus Statement of the ESC Working Group on Cardiovascular Surgery, the ESC Working Group on Cardiovascular Pharmacotherapy, and the European Association for Cardio-Thoracic Surgery (EACTS).

  2025cites this paper
• 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

  2025cites this paper
• Comparison of clopidogrel monotherapy versus prolonged DAPT based on the GRACE risk score in patients with acute coronary syndromes at High Ischemic and Bleeding Risk: a subgroup analysis of the OPT-BIRISK randomized clinical trial.

  2025cites this paper
• Validation of a machine learning model for predicting gastrointestinal bleeding in patients with direct oral anticoagulants

  2025cites this paper
• Efficacy of Ticagrelor Monotherapy in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Intervention: a Systematic Review

  2025influential citation
• Dual Antiplatelet Therapy in NSTEMI: Successfully Navigating the DAPT Dilemma

  2025cites this paper
• Long-term Antithrombotic Therapy in Patients With Chronic Coronary Syndrome: An Updated Review of Current Evidence.

  2025cites this paper